Toll-Like Receptor 2 or Toll-Like Receptor 4 Deficiency Does Not Modify Lupus in MRLIpr Mice

Simon J. Freeley1, Angela Giorgini1, Calogero Tulone1, Reena J. Popat1, Catherine Horsfield2, Michael G. Robson1*

1 MRC Centre for Transplantation King’s College London, London, United Kingdom, 2Department of Histopathology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by involvement of many organs including skin, joints, kidneys and brain. Autoimmunity to nucleic acid associated antigens, including dsDNA, histones, and RNA associated proteins leads to immune complex formation and tissue damage. Glomerulonephritis is a particularly serious clinical manifestation and can lead to irreversible renal failure. Toll-like receptors (TLRs) are a family of structurally related molecules that recognise pathogen-associated molecular patterns. They can be broadly divided into cell-surface receptors such as TLR2 and TLR4 recognising bacterial products, and intracellular receptors such as TLR3, TLR7, TLR8 and TLR9 recognising nucleic acids. They have multiple effects on leukocytes and stromal cells, and influence both innate and adaptive immunity. Previous work has shown that endotoxin, now known to be a TLR4 agonist, can exacerbate disease in a variety of strains of lupus-prone mice [1]. More recently it has been shown that exogenously administered agonists of TLR3, TLR7 and TLR9 can exacerbate murine lupus [1,2,3,4]. In addition several studies using the nephrotoxic nephrin model have shown a role for TLR2 and TLR4 through a number of mechanisms [5,6,7,8]. Together these data support the idea that TLRs play a role in the exacerbation of lupus by bacterial and viral infection, as can be observed clinically.

In addition the potential roles of TLRs in the absence of exogenous ligand administration has been explored. Published work suggests several mechanisms by which TLR7 and TLR9 could facilitate the loss of tolerance to nucleic acid-associated antigens through B cells and dendritic cells [9,10,11,12]. The role of TLR9 and TLR7 has been tested in vivo in murine models of SLE. Initial results on the role of TLR9 in the MRL/lpr mouse were conflicting, but this appears to be resolved with the conclusion that there are less autoantibodies, but worse nephritis in TLR9 deficient lupus-prone mice [13]. TLR7 deficient lupus prone mice on the other hand show less autoantibodies and less severe disease in both the MRL/lpr model and a transgenic lupus model [13,14]. Recent work has suggested that TLR2 and TLR4 may also play a role in murine lupus in the absence of exogenous ligand administration [15]. C57BL/6 (lpr/lpr) mice deficient in TLR2 or TLR4 were studied and found to have reduced anti-dsDNA antibodies and glomerular IgG deposits, though anti-nucleosome antibodies were not affected. Pristane-induced lupus was studied in C57BL/6 TLR4 deficient mice and both autoantibodies and nephritis was found to be ameliorated compared to controls [16].

Nephritis is relatively mild in both C57BL/6-lpr/lpr and in pristane-induced lupus. In contrast MRL/Mp-TgN(Tcl/lpr) mice (abbreviated to MRL/lpr) mice are one of the most robust and frequently used models of murine lupus, and mice develop severe nephritis by 18 weeks of age. There have been no publications addressing the role of TLR2 or TLR4 in this model. We therefore decided to examine if the findings suggesting a role for TLR2 and TLR4 in the milder lupus models would be confirmed in MRL/lpr mice.

* E-mail: Michael.robson@kcl.ac.uk

Citation: Freeley SJ, Giorgini A, Tulone C, Popat RJ, Horsfield C, et al. (2013) Toll-Like Receptor 2 or Toll-Like Receptor 4 Deficiency Does Not Modify Lupus in MRLIpr Mice. PLoS ONE 8(9): e74112. doi:10.1371/journal.pone.0074112

Editor: George C. Tsokos, Beth Israel Deaconess Medical Center, United States of America

Accepted January 8, 2013; Accepted August 1, 2013; Published September 24, 2013

Copyright: © 2013 Freeley et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by the Genzyme Renal Innovations Program and the Sir Jules Thorn Charitable Trust. The authors acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust. The authors also acknowledge the support of the MRC Centre for Transplantation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by involvement of many organs including skin, joints, kidneys and brain. Autoimmunity to nucleic acid associated antigens, including dsDNA, histones, and RNA associated proteins leads to immune complex formation and tissue damage. Glomerulonephritis is a particularly serious clinical manifestation and can lead to irreversible renal failure. Toll-like receptors (TLRs) are a family of structurally related molecules that recognise pathogen-associated molecular patterns. They can be broadly divided into cell-surface receptors such as TLR2 and TLR4 recognising bacterial products, and intracellular receptors such as TLR3, TLR7, TLR8 and TLR9 recognising nucleic acids. They have multiple effects on leukocytes and stromal cells, and influence both innate and adaptive immunity. Previous work has shown that endotoxin, now known to be a TLR4 agonist, can exacerbate disease in a variety of strains of lupus-prone mice [1]. More recently it has been shown that exogenously administered agonists of TLR3, TLR7 and TLR9 can exacerbate murine lupus [1,2,3,4]. In addition several studies using the nephrotoxic nephrin model have shown a role for TLR2 and TLR4 through a number of mechanisms [5,6,7,8]. Together these data support the idea that TLRs play a role in the exacerbation of lupus by bacterial and viral infection, as can be observed clinically.

In addition the potential roles of TLRs in the absence of exogenous ligand administration has been explored. Published work suggests several mechanisms by which TLR7 and TLR9 could facilitate the loss of tolerance to nucleic acid-associated antigens through B cells and dendritic cells [9,10,11,12]. The role of TLR9 and TLR7 has been tested in vivo in murine models of SLE. Initial results on the role of TLR9 in the MRL/lpr mouse were conflicting, but this appears to be resolved with the conclusion that there are less autoantibodies, but worse nephritis in TLR9 deficient lupus-prone mice [13]. TLR7 deficient lupus prone mice on the other hand show less autoantibodies and less severe disease in both the MRL/lpr model and a transgenic lupus model [13,14]. Recent work has suggested that TLR2 and TLR4 may also play a role in murine lupus in the absence of exogenous ligand administration [15]. C57BL/6 (lpr/lpr) mice deficient in TLR2 or TLR4 were studied and found to have reduced anti-dsDNA antibodies and glomerular IgG deposits, though anti-nucleosome antibodies were not affected. Pristane-induced lupus was studied in C57BL/6 TLR4 deficient mice and both autoantibodies and nephritis was found to be ameliorated compared to controls [16].

Nephritis is relatively mild in both C57BL/6-lpr/lpr and in pristane-induced lupus. In contrast MRL/Mp-TgN(Tcl/lpr) mice (abbreviated to MRL/lpr) mice are one of the most robust and frequently used models of murine lupus, and mice develop severe nephritis by 18 weeks of age. There have been no publications addressing the role of TLR2 or TLR4 in this model. We therefore decided to examine if the findings suggesting a role for TLR2 and TLR4 in the milder lupus models would be confirmed in MRL/lpr mice.
Materials and Methods

Ethics Statement

All animal experiments were performed according to Institutional and Home Office regulations (PPL 70/6617). All efforts were made to minimize suffering.

Mice

TLR2 and TLR4 deficient mice originally obtained from S Akira and backcrossed to C57BL/6 were mated with MRL/lpr/lpr mice (abbreviated to MRL-lpr) purchased from Harlan UK. TLR deficient mice were each backcrossed 7 generations with MRL-lpr mice with presence of the TLR2 or TLR4 knockout locus confirmed by PCR. After 7 generations, we confirmed with PCR that all mice were homozygous for the Tnfrsf6lpr/lpr mutation. Since MRL-lpr mice are MHC haplotype H2k and C57BL/6 mice are H2b, we confirmed that, after 7 generations of backcrossing, all mice were homozygous for H2b using PCR and restriction enzyme digestion according to a published method [17]. Backcrossed mice heterozygous for TLR2 were interbred to give mice that were homozygous for TLR2 deficiency (denoted MRL-lprTLR2+/−) or TLR2 sufficient littermate controls (denoted MRL-lprTLR2+/+). PCR primer pairs were as follows. TLR2 deficient 5′-GTT TAG TGC CTT TAT CCA GTC AGT GCC GCC TCC-3′. TLR2 wildtype 5′-ATC GCC TTC TAT CGC CTT CCT GAC GAG-3′ and 5′-TTG TGG GTC GTT TGT TCG GAT CCG TCG-3′. Mice heterozygous for TLR2 were not studied. MRL-lprTLR4−/− mice and MRL-lprTLR4+/− littermate controls were generated in a similar fashion. PCR primer pairs were as follows. TLR4 deficient 5′-CGT GTA AAC CAG CCA GGT TTT GAA GGC-3′ and 5′-TTG TCG CCT TCA GTC ACA GAG ACT CTG-3′. TLR4 wildtype 5′-TGT TGG GTG TGT TGG TCA GCG TTC TGC-3′ and 5′-TGT TGG CCA CTC TCA GTC ACA GAG ACT CTG-3′.

Figure 1. The effect of TLR2 or TLR4 deficiency on survival. A. Survival data for MRL-lpr mice and TLR4 deficient littermate controls. B. Survival data for MRL-lpr mice and TLR2 deficient littermate controls. There were no significant differences in either case.

doi:10.1371/journal.pone.0074112.g001

Histology

Renal tissue was fixed in Bouin’s solution, embedded in paraffin, stained with Period acid-Schiff, and evaluated by an expert renal pathologist (CH). Glomerulonephritis was graded 0–3 according to the following scheme: grade 0, normal; grade 1, endocapillary proliferation (>50% of glomerulus) in 25–50% of glomeruli; grade 2, endocapillary proliferation (>50% of the glomerulus) in 50–75% of glomeruli; grade 3, endocapillary proliferation (>50% of the glomerulus) in >75% of the glomeruli or crescents in >25% of glomeruli. A minimum of 50 glomeruli per sample were assessed for the analysis. Kidney was frozen in isopentane, and cryostat sections were stained with FITC conjugated goat anti-mouse IgG (Jackson’s Immunoresearch), or with monoclonal rat anti-mouse C3 (Cedar Lane) followed by DyLight488 mouse anti-rat IgG (Jackson’s Immunoresearch). To quantify IgG and C3 deposition, a minimum of 20 glomeruli per section were photographed at×200 magnification with an Olympus BX51 fluorescent microscope. Glomeruli were manually drawn around using ImageJ software (National Institute of Health), and the mean fluorescence intensity within the defined area measured to give a quantitative value. This process was performed without knowledge of sample identity.

Serology and Biochemistry

Mice were bled at 14 weeks, and blood was also taken at 18 weeks from surviving mice. Spot urines were taken from mice at 14 and 18 weeks. Serum and urine creatinine was measured by electrospray mass spectroscopy in a clinical biochemistry laboratory. Urinary albumin was measured using an ELISA from Bethyl laboratories (Montgomery, Texas, USA) according to the manufacturer’s instructions. Anti-dsDNA antibodies were measured by ELISA. Nunc Maxisorb ELISA plates (Fischer Scientific, Leciester, UK) were coated with poly-L-Lysine, then with 5 µg/ml of calf thymus DNA (Sigma, Poole, UK) in TE buffer. Plates were treated with S1 nuclease (Sigma) in 30 mM sodium acetate, pH 4.6, 50 mM NaCl, 1 mM ZnCl2, in order to remove single stranded DNA. For the anti-ssDNA ELISA, wells were coated with 5 µg/ml of calf thymus DNA which had been heated at 100°C for 10 minutes. For the anti-dsDNA and anti-ssDNA ELISAs, samples were applied at 1 in 2000 and 1 in 800 dilutions respectively, followed by an alkaline phosphatase conjugated goat anti-mouse IgG detection antibody (Southern Biotechnology). A standard curve was generated from a reference serum and levels in samples were expressed in arbitrary units relative to this standard. Total serum IgG subclasses and IgM were assessed by capture ELISAs, samples were applied at 1 in 2000 and 1 in 800 dilutions respectively, followed by an alkaline phosphatase conjugated goat anti-mouse IgG detection antibody (Southern Biotechnology). A standard curve was generated from a reference serum and levels in samples were expressed in arbitrary units relative to this standard. Total serum IgG subclasses and IgM were assessed by capture
ELISA. The capture antibody was 5 μg/ml of goat anti-mouse immunoglobulin (Southern Biotech), and serum was applied at an appropriate dilution (1 in 120,000 for IgG subclasses and 1 in 4000 for IgM). Alkaline phosphatase conjugated goat antibodies (Southern Biotechnology) was used for detection, and were specific for IgG1, IgG2a, IgG2b, IgG3 or IgM. For each ELISA a standard curve was generated from a reference serum and levels in samples were expressed in arbitrary units relative to this standard.

Crithidia Lucillae titre was measured using commercial slides (Binding Site, Birmingham, UK) and the lowest titre at which fluorescence was positive by a blinded observer assessed with a BX51 fluorescent microscope (Olympus, Southend-on-sea, UK).

**Statistics**

Data were analysed with Graphpad prism (San diego, CA) software using a Mann-Whitney U for Crithidia titres and histology scores. A Student’s t-test was used for other data, after a logarithmic transformation of the data if appropriate. Survival curves were analysed with a logrank test.

**Results**

Nephritis is not Modified by TLR2 or TLR4 Deficiency

We first assessed the severity of kidney disease in cohorts of mice at 18 weeks. In the first experiment, 13 MRLlpr mice and TLR2 deficient littermate controls were compared, with no significant differences for either analysis. Each symbol is an individual mouse.

- **A**: Histology data showing severity of glomerulonephritis for MRLlpr mice and TLR2 deficient littermate controls at 18 weeks, with representative histology on PAS stained sections shown below. There were no significant differences for either analysis. Each symbol is an individual mouse.
- **B**: Histology data showing severity of glomerulonephritis for MRLlpr mice and TLR4 deficient littermate controls at 18 weeks, with representative histology on PAS stained sections shown below. There were no significant differences for either analysis. Each symbol is an individual mouse.
- **C**: Urine albumin creatinine ratio at 14 weeks for MRLlpr mice and TLR2 deficient littermate controls, and for MRLlpr mice and TLR4 deficient littermate controls.
- **D**: Urine albumin creatinine 18 weeks for these same groups. (Note one data point is missing in the TLR4 deficient group at week 18 as no urine was obtained).
- **E**: Serum creatinine at 18 weeks in MRLlpr mice and TLR2 deficient littermate controls and for MRLlpr mice and TLR4 deficient littermate controls. Each symbol is an individual mouse. NS = not significant.

Figure 2. Histological and functional assessment of glomerulonephritis. A. Histology data showing severity of glomerulonephritis for MRLlpr mice and TLR2 deficient littermate controls at 18 weeks with representative histology, showing varying degrees of proliferative nephritis, on PAS stained sections shown below. B. Histology data showing severity of glomerulonephritis for MRLlpr mice and TLR4 deficient littermate controls at 18 weeks, with representative histology on PAS stained sections shown below. C. Urine albumin creatinine ratio at 14 weeks for MRLlpr mice and TLR2 deficient littermate controls, and for MRLlpr mice and TLR4 deficient littermate controls. D. Urine albumin creatinine 18 weeks for these same groups. (Note one data point is missing in the TLR4 deficient group at week 18 as no urine was obtained). E. Serum creatinine at 18 weeks in MRLlpr mice and TLR2 deficient littermate controls and for MRLlpr mice and TLR4 deficient littermate controls. Each symbol is an individual mouse. NS = not significant.
deficient MRLlpr sex-matched littermate controls were compared. All mice survived to 14 weeks, though by 18 weeks two TLR2 sufficient mice had died, leaving 11 in each group for analysis. In the second experiment, 15 MRLlpr and 15 TLR4 deficient MRLlpr sex-matched littermate controls were compared. One TLR4 deficient mouse died at 13 weeks, and by 18 weeks 4 more TLR4 deficient mice and 3 TLR4 sufficient mice had died (not significant), leaving 12 TLR4 sufficient and 10 TLR4 deficient MRLlpr mice for analysis respectively. There were no significant differences in survival curves for either experiment as shown in figure 1. Glomerulonephritis was histologically graded, and there was no significant difference between MRLlpr and their TLR2 deficient MRLlpr littermate controls. In addition there was no significant difference in histology between MRLlpr and their

Figure 3. Glomerular deposition of IgG and C3 was assessed as described under methods. A–B shows data for IgG deposition in the two experiments with TLR deficient mice compared with littermate controls, and C–D shows data for C3 deposition. Each symbol is an individual mouse. NS = not significant. A photomicrograph showing representative immunofluorescence staining is shown underneath the corresponding group of mice in panels A–D.
doi:10.1371/journal.pone.0074112.g003
Figure 4. Assessment of autoimmunity. A–B. Spleen weights for MRLlpr mice and their TLR2 or TLR4 deficient littermate controls at 18 weeks (Note six data points were lost in panel B to a technical error). C. Anti-dsDNA antibodies measured by ELISA (left) at 14 and 18 weeks in MRLlpr mice and TLR2 deficient littermate controls. D. Anti-dsDNA antibodies were also measured by *Crithidia Lucillae* fluorescence at 18 weeks in MRLlpr mice and TLR2 deficient littermate controls. E. Anti-dsDNA antibodies measured by ELISA (left) at 14 and 18 weeks in MRLlpr mice and TLR4 deficient littermate controls. F. Anti-dsDNA antibodies were also measured by *Crithidia Lucillae* fluorescence at 18 weeks in MRLlpr mice and TLR4 deficient littermate controls. Each symbol is an individual mouse. NS = not significant.
TLR4 deficient MRL/lpr littermate controls. Figure 2A–B shows histology data and representative histology. In order to assess the functional severity of disease, we measured urinary albumin creatinine ratio at both week 14 and week 18, and serum creatinine at week 18. Again no significant differences were detected between groups. These functional data are shown in figure 2C–E. We also analysed glomerular deposition of IgG and C3 in all mice from each experiment and no differences were found, as shown in figure 3.

Autoimmunity is not Modified by TLR2 or TLR4 Deficiency

Although we had found no evidence that kidney disease was modified by the absence of TLR2 or TLR4, it remained possible that there was modulation of autoimmunity in TLR2 or TLR4 deficient MRL/lpr mice. However there was no difference in spleen weights between MRL/lpr and TLR4 deficient MRL/lpr littermate controls and also no difference when MRL/lpr and TLR2 deficient MRL/lpr littermate controls were compared, as shown in figure 3A. We also measured anti-dsDNA antibodies, in all mice at both 14 and 18 weeks using an ELISA-based method. We confirmed the week 18 data with a semi-quantitative *Crithidia Lucillae* assay, and all mice had anti-dsDNA antibodies detected by both assays. There were no differences between TLR2 deficient MRL/lpr TLR2−/− mice and littermate controls (figure 4B), or between MRL/lprTLR4−/− mice and littermate controls (figure 4C). We also analysed levels of IgG subclasses and IgM at 18 weeks in all mice. There were no significant differences when MRL/lpr mice and TLR4 deficient MRL/lpr littermate controls as shown in figure 5 A–J. When MRL/lpr mice and TLR2 deficient MRL/lpr littermate controls were compared there were higher levels of IgG2a and IgG2b, but no difference in levels of other subclasses or IgM. Levels of anti-ssDNA antibodies were also measured with no significant differences found (figure 5 K–L).

**Discussion**

In this study we have demonstrated that neither TLR2 nor TLR4 deficiency modulates autoantibody production or glomerulonephritis in MRL/lpr mice. These data suggest that in the presence of a strong genetic predisposition to lupus, the role of TLR2 or TLR4 is not significant. Although the result is surprising given the previous data in milder lupus models suggesting these TLRs are important, our data do not in any way invalidate or question the results obtained in these previous studies. In our study, care was taken to use littermate controls and to confirm homozygosity for the MRL H2 haplotype, meaning that genetic variation is very unlikely to account for the lack of an observed difference between the cohorts. Robust disease was seen, with some mortality, significant proteinuria, and severe glomerulonephritis at 18 weeks which is consistent with published reports.

Our data cannot exclude the possibility that there were histological differences between groups at timepoints earlier than 18 weeks. However there were no differences in the survival curves, and when we analysed anti-dsDNA antibodies at week 14 and there were no differences. A difference in the tempo of disease induction therefore seems unlikely. We did find higher levels of IgG2a and IgG2b in TLR2 deficient MRL/lpr mice. The significance of this is not clear, but it does not suggest that TLR2 deficiency inhibits the autoimmune phenotype.

Proposed endogenous ligands for TLR2 and TLR4 include heat-shock proteins, heparan sulphate, fibrinogen, biglycan, hyaluronic acid and high mobility group box protein 1 (HMGB1). These molecules are likely to be released during end-organ inflammation such as glomerulonephritis in SLE. These ligands have been shown to activate TLR2 and TLR4 in both in vitro and also in vivo systems (13–18). Therefore, even in the absence of an effect on autoantibody levels, we may have anticipated an effect on the severity of glomerulonephritis. A recent report has demonstrated a role for biglycan in MRL/lpr lupus [18]. Overexpression exacerbated disease, and deficiency diminished disease. The mechanism of this effect was thought to depend on the B cell chemokine CXCL13 which was released in a TLR2/TLR4 dependent manner. This finding would predict that lupus would be attenuated in MRL/lpr mice deficient in TLR2 or TLR4. There are at least two potential reasons for this discrepancy. Firstly biglycan is also a ligand for the receptor PTX7 although the release of CXCL13 was found to depend on TLR2/4 rather than PTX7. Nonetheless, there may be an additional role for PTX7 in biglycan-mediated effects. In addition, there may be some redundancy since biglycan may act via either TLR2 or TLR4. Therefore we cannot be sure that combined deficiency of TLR2 and TLR4 would not have resulted in protection from lupus in MRL/lpr mice where none was seen with deficiency in just one receptor. HMGB1, a nucleosome binding protein has been shown to be present at increased levels in the plasma of SLE patients, and to stimulate dsDNA antibody production in mice in TLR dependent manner [19]. HMGB1 has also been shown to act via both TLR2 and TLR4 which further raises the possibility that deficiency a combined deficiency of both TLR2 and TLR4 might have shown an effect MRL/lpr mice. These experiments would certainly be of interest and could form the basis for future work.

**Conclusions**

Our data directly examines the role of TLR2 and TLR4 in one of the commonly used strains with a genetic predisposition to robust lupus-like disease. We have not demonstrated a role for TLR2 or TLR4, and we suggest that these may not be useful therapeutic targets in SLE. Further preclinical data in other lupus-prone strains will be required to clarify this further.

**Acknowledgments**

We are grateful to Charles Turner and Neil Dalton at Guys and St Thomas’ Hospitals for expert help with creatinine measurements. We are also grateful to Shizuo Akira for providing the TLR2 and TLR4 deficient mice.

**Author Contributions**

Conceived and designed the experiments: SJF AG CT RP CH MGR. Performed the experiments: SJF AG CT RP CH MGR. Analyzed the data: SJF AG CT RP CH MGR. Wrote the paper: MGR.
References

1. Hang L, Slack JH, Amundson C, Izui S, Theofilopoulos AN, et al. (1983) Induction of murine autoimmune disease by chronic polyclonal B cell activation. J Exp Med. 157: 874–83.

2. Anders HJ, Krug A, Pawar RD (2008) Molecular mimicry in innate immunity? The viral RNA recognition receptor TLR7 accelerates murine lupus. Eur J Immunol. 38: 1795–9.

3. Patole PS, Pawar RD, Lech M, Zecher D, Schmidt H, et al. (2006) Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol Dial Transplant. 21: 3062–73.

4. Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, et al. (2006) Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol. 17: 141–9.

5. Brown HJ, Lock HR, Sacks SH, Robson MG (2006) TLR2 stimulation of intrinsic renal cells in the induction of immune-mediated glomerulonephritis. J Immunol. 177: 1925–31.

6. Brown HJ, Lock HR, Wolff TG, Baarman WA, Sacks SH, et al. (2007) Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2. J Am Soc Nephrol. 18: 1732–9.

7. Brown HJ, Sacks SH, Robson MG (2006) Toll-like receptor 2 agonist exacerbates accelerated nephrotoxic nephritis. J Am Soc Nephrol. 17: 1931–9.

8. Giorgini A, Brown HJ, Sacks SH, Robson MG (2010) Toll-like receptor 4 stimulation triggers crescentic glomerulonephritis by multiple mechanisms including a direct effect on renal cells. Am J Pathol. 177: 644–53.

9. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, et al. (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 416: 603–7.

10. Means TK, Latta E, Hayashi F, Murali MR, Golenbock DT, et al. (2005) Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 115: 407–17.

11. Vollmer J, Thik S, Schmitz C, Hanum S, Jurk M, et al. (2005) Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med. 202: 1573–85.

12. Lau CM, Broughton C, Tabor AS, Akira S, et al. (2005) RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 202: 1171–7.

13. Christensen SK, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, et al. (2005) Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med. 202: 321–31.

14. Berland R, Fernandez L, Kari E, Han JH, Lomakin I, et al. (2006) Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity. 25: 429–40.

15. Lartigue A, Colliou N, Calbo S, Francois A, Jacquot S, et al. (2009) Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol. 183: 6207–16.

16. Summers SA, Hsi A, Steinmetz OM, O’Sullivan KM, Ooi JD, et al. (2010) TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun. 35: 291–8.

17. Peng SL, Craft J (1996) PCR-RFLP genotyping of murine MHC haplotypes. Biotechniques. 21: 362, 366–8.

18. Moreth K, Brodbeck R, Babelow A, Gretz N, Spieker T, et al. (2010) The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest. 120: 4251–72.

19. Ubranoviciute V, Furrauhr BG, Meister S, Munoz L, Heyder P, et al. (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 205: 3007–18.